pharmaphorum2d
Another NASH setback as Akero’s efruxifermin stumbles
Last year, Akero trumpeted the results of the HARMONY study in less ill patients with stage 2 or 3 fibrosis ... that patients with cirrhosis due to NASH face a bleak prognosis, as, unless they ...
Medscape2d
Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...
pharmaphorum8d
Gilead NASH drug fails late stage trial
Gilead's top late-stage drug selonsertib ... 3 trial of selonsertib in patients with bridging fibrosis due to NASH and the phase 2 ATLAS combination trial of selonsertib, cilofexor (GS-9674 ...
Hosted on MSN9mon
What's Happening With Eli Lilly Shares On Monday?
The SYNERGY-NASH study was a multicenter ... s efficacy and safety at various doses in adults with MASH and stage 2 or 3 fibrosis. Tirzepatide is a once-weekly GIP and GLP-1 receptor agonist.
Medscape15d
Beneficial Effects of Pentoxifylline on Hepatic Steatosis, Fibrosis and Necroinflammation in Patients With Non-alcoholic Steatohepatitis
In conclusion, pentoxifylline leads to a significant reduction in the AST and ALT levels in patients with NASH. This improvement ... inflammation and fibrosis stage. Randomized controlled trials ...